Aethlon Medical announces publication of study on its Hemopurifier

Aethlon Medical (AEMD) announced the publication of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, “Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin, or GNA, affinity resin.” Aethlon Medical’s Hemopurifier is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles, or EVs or exosomes, and life-threatening viruses from blood and other biological fluids, properties that support its evaluation not only in oncology and infectious diseases, but also in the organ transplantation and other areas of significant unmet medical need. Platelet-derived extracellular vesicles are the most numerous EV population in the body and are released by platelets in response to a variety of stimuli. The cargo contained within these EVs have been noted to participate in damage to blood vessels, activation of immune cells, and spread of tumor cells. Excessive levels of PD-EVs have been implicated in a myriad of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer’s disease, sepsis, acute and Long COVID. Next steps will be to submit the findings of this study to a peer-review medical journal and specifically study PD-EV removal and their cargo from plasma samples from diseases of interest.